Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

74.51 0.41 −0.55%
Market cap
$237.8M
P/E
22.7×
Fwd P/E
28.7×
Dividend yield
1.66%
F-score
6/9
Altman Z
36.25
Beneish M
−2.68
Dividend safety
82/100
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
9 6 5 8 6 9 7 6 6 6
P/E ratio
22.24 34.63 16.78 27.39 28.77 24.69 21.68 18.27 15.56 16.08
P/S ratio
6.82 7.12 7.38 8.56 7.31 7.43 6.80 6.03 5.26 4.71
Altman Z-Score
26.77 15.40 20.37 30.64 23.54 28.83 25.99 28.77 28.36 36.25
Altman Z″-Score (non-manufacturers)
18.07 13.10 16.86 19.65 19.59 21.52 21.31 27.94 33.27 47.39
P/FCF ratio
23.86 19.27 17.92 0.00 0.00 0.00 17.49 14.00 14.73 12.66
Beneish M-Score
(2.83) (3.00) (2.37) (2.23) (3.08) (2.59) (2.85) (3.06) (2.12) (2.68)
P/Operating CF
79.12 64.30 69.13 71.17 53.37 73.13 62.60 56.82 73.32 52.15
P/B ratio
3.87 3.77 3.48 3.97 3.00 3.40 3.11 2.36 1.83 1.52
Dividend Safety Score
— — — — — — — — — 82
Price to Tangible BV
7.14 6.38 5.12 7.05 4.77 4.84 3.93 2.76 2.13 1.74
EV/Sales
6.17 6.18 6.18 7.67 6.11 6.21 5.38 4.20 3.26 2.51
EV/EBITDA
12.75 11.75 12.00 14.67 12.32 11.65 10.47 9.12 8.11 6.70
EV/Operating CF
16.69 15.13 15.43 21.09 12.80 14.37 13.31 9.47 8.99 6.57
EV/FCF
21.60 16.72 15.02 (80.21) (149.60) (873.06) 13.85 9.75 9.12 6.74
Quick Ratio
9.79 8.25 10.47 13.78 14.69 17.65 13.52 20.44 23.18 34.36
Current Ratio
11.41 9.32 11.58 15.92 16.42 19.53 15.09 22.56 25.64 37.62
Net Debt/EBITDA
(1.39) (1.83) (2.36) (1.75) (2.47) (2.33) (2.79) (4.01) (5.05) (5.95)
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.51 0.49 0.44 0.45 0.38 0.43 0.44 0.39 0.32 0.31
Operating CF/Net income
1.20 1.99 0.91 1.16 1.86 1.43 1.28 1.34 1.07 1.30
Capex/Depreciation
(1.17) (0.58) 0.16 (3.13) (0.12) (0.08) (0.12) (0.10) (0.07) (0.12)
Interest Coverage
1,348.92 1,118.29 86.16 69.42 122.39 113.73 29.94 — — —
ROE
17.46% 11.54% 22.21% 15.50% 10.59% 14.09% 14.88% 13.72% 11.29% 9.54%
ROA
15.61% 10.07% 19.28% 14.06% 9.75% 13.01% 13.76% 12.83% 10.76% 9.21%
ROIC
23.59% 31.13% 30.85% 18.90% 16.72% 25.56% 31.55% 29.58% 24.66% 21.26%
Return on Tangible Assets
29.28% 15.32% 28.11% 23.69% 15.47% 18.48% 17.49% 14.84% 13.56% 10.74%
Average Days of Receivables
29.82 31.93 34.38 36.90 35.52 38.19 38.66 24.64 36.53 33.37
Research and Development Expense of Revenue
1.21% 1.08% 1.08% 1.03% 1.15% 1.07% 0.94% 1.12% 1.99% 1.73%
Selling, General and Administrative Expense of Revenue
17.88% 16.75% 17.04% 24.20% 26.92% 23.47% 22.79% 25.29% 23.80% 25.78%
Intangible Assets out of Total Assets
0.42 0.34 0.29 0.40 0.34 0.28 0.19 0.14 0.13 0.12
Share Based Compensation of Revenue
0.23% 0.31% 0.15% 0.24% 0.38% 0.34% 0.35% 0.45% 0.63% 0.97%
Graham Net Nets
0.10 0.12 0.16 0.12 0.17 0.18 0.23 0.33 0.42 0.52
Graham Number
36.51 32.90 51.55 49.08 43.05 51.74 56.46 60.30 54.58 53.69
Earnings Yield
4.50% 2.89% 5.96% 3.65% 3.48% 4.05% 4.61% 5.47% 6.43% 6.22%
Free Cash Flow Yield
4.19% 5.19% 5.58% (1.12%) (0.56%) (0.10%) 5.72% 7.14% 6.79% 7.90%
Revenue per Share
10.48 11.14 11.26 12.61 11.53 13.45 14.37 13.84 11.68 11.89
Operating CF per Share
3.87 4.55 4.51 4.58 5.50 5.81 5.81 6.14 4.23 4.53
Capex per Share
(0.88) (0.43) 0.12 (5.79) (0.24) (0.15) (0.22) (0.18) (0.06) (0.11)
Free Cash Flow per Share
2.99 4.12 4.64 (1.21) 5.27 5.66 5.59 5.96 4.17 4.42
Cash per Share
7.03 10.75 13.70 11.50 14.10 16.72 20.64 25.59 23.69 26.47
Shareholders Equity per Share
18.46 21.01 23.86 27.17 28.11 29.38 31.41 35.36 33.52 36.81
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
18.46 21.01 23.86 27.17 28.11 29.38 31.41 35.36 33.52 36.81
Free Cash Flow
11.23 15.31 17.29 (4.48) 19.28 20.65 20.33 21.64 14.62 14.32
Working Capital
31.45 43.91 55.64 51.44 58.47 69.41 83.96 101.56 92.57 95.14
Capital Expenditures
(3.30) (1.60) 0.46 (21.54) (0.86) (0.55) (0.82) (0.64) (0.21) (0.37)
Net Current Asset Value
27.53 34.57 50.13 46.19 53.34 64.66 80.30 99.12 91.22 94.47
EV/EBIT
14.98 13.46 13.89 20.40 18.80 16.14 14.22 12.58 9.81 8.47
Capex to Sales
0.08 0.04 (0.01) 0.46 0.02 0.01 0.02 0.01 0.01 0.01
Price to Operating Income
16.55 15.51 16.57 22.77 22.50 19.32 17.97 18.06 15.84 15.90
Other line items
Depreciation/Fixed assets
0.28 0.24 0.29 0.64 0.64 0.69 0.69 0.60 0.29 0.30
Cash ROIC
11.74% 12.97% 12.34% (3.12%) 12.48% 12.28% 10.74% 9.78% 7.30% 6.99%
Accounts Receivable Turnover
10.11 12.12 11.08 10.79 9.54 10.62 9.80 11.25 10.93 10.12
Accounts Payable Turnover
20.07 16.33 16.44 16.82 17.64 23.42 20.30 20.32 22.88 20.56
Inventory Turnover
3.57 3.07 2.95 2.83 2.53 2.83 2.61 2.19 1.82 1.97
Average Days of Payables
21.19 22.70 22.68 22.98 17.30 15.31 22.13 13.90 15.16 20.13
Days of Inventory on Hand
106.22 127.44 125.88 144.72 136.56 132.74 160.17 173.26 191.91 175.33
Average Receivables
3.89 3.42 3.79 4.35 4.42 4.62 5.34 4.46 3.74 3.81
Average Payables
0.78 0.92 0.95 1.04 0.94 0.77 0.99 0.99 0.73 0.80
Average Inventory
4.37 4.89 5.33 6.16 6.57 6.41 7.71 9.20 9.20 8.37
Average Assets
77.68 84.47 96.26 104.78 110.77 113.69 119.76 129.67 129.00 122.54
Average Common Equity
69.45 73.68 83.56 95.04 101.96 104.98 110.70 121.28 122.87 118.35

Fold the line items

Columns are period end dates